Skip to content
DataLookout
Menu

NCT07222267

An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 19 versions: 19 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment increased: 86 → 186 participants Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 46 words
    • Secondary endpoints: 14 to 12
    • Study description expanded, about 234 words
    • Study title shortened, about 1 word
  2. Minor Site details revised at 1 of 32 sites
  3. Notable Eligibility criteria expanded, about 11 words
    • Study sites: 31 to 32
    • Secondary endpoints: details revised at 3 of 14 entries
  4. Minor Study sites: 30 to 31v16
  5. Minor Study sites: 29 to 30v15
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Study sites: 27 to 29v14
  2. Minor Study sites: 25 to 27v13
  3. Minor Study sites: 23 to 25v12
  1. Minor Trial sites expanded: 20 → 23 locationsv11
  2. Minor Trial sites expanded: 12 → 20 locationsv10
  3. Minor Study sites: 10 to 12v9
  4. Minor Primary completion date: Apr 30, 2029 to Sep 30, 2029
    • Study completion date: Jul 31, 2036 to Jan 13, 2037
    v8
  5. Minor Study sites: 9 to 10v7
  6. Minor Study sites: 5 to 9v6
  7. Minor Study sites: 3 to 5v5
  8. Minor Study sites: 2 to 3v4
  9. Minor Study sites: 1 to 2v3
  10. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 2025 to Dec 11, 2025
    • Study site revised
    v2
  11. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Part 1 and Part 2B (Safety Lead-in): Number of Participants with Adverse Events (AEs)
Timeframe: From first dose to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately 12 months
Part 1 and Part 2B (Safety Lead-in): Recommended Dose for Expansion (RDFE)
Timeframe: Estimated approximately 1 year
Part 2 A and Part 2C: Overall Response Rate (ORR)
Timeframe: Up to approximately 2 years

Secondary (12)

Part 1 and Part 2B (Safety Lead-in): ORR
Duration of Response (DOR)
Disease Control Rate (DCR)
Clinical Benefit Rate (CBR)
Part 2: Time to Response (TTR)
Show 7 moreShow less
Part 2A and Part 2C: Progression-Free Survival (PFS)
Part 2A and Part 2C: Number of Participants with Adverse Events (AEs)
Part 2A and Part 2C: Recommended Phase 2 Dose (RP2D) or Recommended Phase 3 Dose (RP3D)
Parts 1 and 2: Maximum Observed Plasma Concentration (Cmax) of BG-75202
Parts 1 and 2: Minimum Observed Plasma Concentration (Ctrough) of BG-75202
Parts 1 and 2: Area Under the Plasma Concentration-Time Curve (AUC) of BG-75202
Parts 1 and 2: Terminal Half-Life (t1/2) of BG-75202

Arms and interventions

Part 1A: Dose Escalation and Safety Expansion, BG-75202 MonotherapyExperimental

Sequential cohorts of increasing dose levels of BG-75202 will be evaluated as monotherapy.

Part 1B: Dose Escalation and Safety Expansion, BG-75202 + Estrogen Receptor AntagonistExperimental

Sequential cohorts of increasing dose levels of BG-75202 will be evaluated in combination with an estrogen receptor antagonist.

Part 2A: Dose Optimization, BG-75202 + Estrogen Receptor AntagonistExperimental

Participants will receive BG-75202 in combination with an estrogen receptor antagonist.

Part 2B: Safety Lead-In, BG-75202 + CDK4 inhibitor + Aromatase InhibitorExperimental

Participants will receive BG-75202 in combination with a cyclin-dependent kinase 4 (CDK4) inhibitor and an aromatase inhibitor.

Part 2C: Dose Expansion, BG-75202 + CDK4 inhibitor + Aromatase InhibitorExperimental

Participants will receive BG-75202 in combination with a CDK4 inhibitor and an aromatase inhibitor.

Drugs: BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor

Sites

32 sites in 6 countries

China 11, United States 6, Australia 5, Spain 5, Italy 4, New Zealand 1